Semaglutide is a medication that belongs to a class of drugs called GLP-1 receptor agonists. It helps control blood sugar levels and can reduce appetite, which leads to weight loss. In this trial, it’s being studied specifically for people who have both type 1 diabetes and obesity. The medication is typically given as an injection under the skin and works by mimicking a natural hormone that helps regulate hunger and food intake.

Type 1 Diabetes – A chronic condition where the pancreas produces little or no insulin, which is a hormone needed to allow sugar to enter cells to produce energy. The immune system attacks and destroys insulin-producing cells in the pancreas. This results in increased blood sugar levels in the body. The condition typically develops during childhood or adolescence, though it can occur at any age.

Obesity – A complex medical condition characterized by excessive accumulation of body fat. It is measured by Body Mass Index (BMI), with values of 30 or higher indicating obesity, while values of 27 or higher with related health conditions are considered clinically significant. The condition develops gradually through an imbalance between calorie intake and energy expenditure. The excess weight puts additional stress on various body systems and can affect overall physical function.